Evaluating Amgen and Sanofi's Individual Needs for Medivation

Medivation Inc. (NASDAQ:MDVN) has lately been under immense media spotlight after the drugmaker became the center of attention for several pharmaceutical giants seeking cancer acquisitions. Medivation has been approached by several companies recently that are eyeing the company’s blockbuster cancer drug, Xtandi.

Sanofi’s Pursuit

So far, however, only Sanofi SA ADR (NYSE:SNY) has publically announced its acquisition proposal.